Sugi Predict

Sugi Predict / Compounds / SCHEMBL282416

SCHEMBL282416

SCHEMBL282416

CCCCN(CCCC)CCCCl

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.56
▸ TDP1 Q9NUW8 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.50
▸ MAPT P10636 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CA12 O43570 2/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ KDM5A P29375 1/20 0.35
▸ HTR1B P28222 1/20 0.35
▸ KCNH2 Q12809 1/20 0.34
▸ DNM1 Q05193 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6139434 0.97 TSHR (0.53) TSHRTDP1ALDH1A1MAPTLMNA
SCHEMBL11835178 0.97 TSHR (0.53) TSHRTDP1ALDH1A1MAPTLMNA
SCHEMBL6061703 0.94 TSHR (0.58) TSHRTDP1ALDH1A1MAPTLMNA
SCHEMBL6946256 0.92 TSHR (0.55) TSHRTDP1ALDH1A1MAPTLMNA
SCHEMBL7681688 0.92 TSHR (0.55) TSHRTDP1ALDH1A1MAPTLMNA
SCHEMBL1885053 0.92 TSHR (0.63) TSHRTDP1ALDH1A1MAPTLMNA
SCHEMBL1879456 0.92 TSHR (0.63) TSHRTDP1ALDH1A1MAPTLMNA
SCHEMBL1884965 0.92 TSHR (0.63) TSHRTDP1ALDH1A1MAPTLMNA
SCHEMBL21842845 0.89 TSHR (0.60) TSHRTDP1ALDH1A1LMNACA12
SCHEMBL6945510 0.89 TSHR (0.60) TSHRTDP1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118225952-B Method for detecting impurities in N- (3-chloropropyl) dibutylamine 石家庄四药有限公司 2025-02-11 — — CN claimed
CN-118225952-A Method for detecting impurities in N- (3-chloropropyl) dibutylamine 石家庄四药有限公司 2024-06-21 — — CN claimed
CN-106892886-B A kind of preparation method of dronedarone hydrochloride 上海华源医药科技发展有限公司 2019-03-05 — — CN claimed
US-9174958-B2 Process for the preparation of dronedarone SANOFI (FR) 2015-11-03 — — US claimed
CN-102070578-B The preparation method of 2-normal-butyl-3-(4-(the amino propoxy-of 3-di-n-butyl) benzoyl)-5-oxoethyl SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2015-10-14 — — CN claimed
CN-102659726-B Method for synthesis of dronedarone FUJIAN COSUNTER PHARMACEUTICAL CO LTD 2014-11-19 — — CN claimed
US-20130109868-A1 Process for the Preparation of Dronedarone SANOFI (FR) 2013-05-02 — — US claimed
EP-2582685-A1 PROCESS FOR THE PREPARATION OF DRONEDARONE SANOFI (FR) 2013-04-24 — — EP claimed
WO-2012120544-A2 PROCESS FOR N-[2-n-BUTYL-3-[4-[3-(DI-n-BUTYLAMINO) PROPOXY]ENZOYL]BENZOFURAN-5-YL]METHANESULFONAMIDE HYDROCHLORIDE SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) 2012-09-13 — — WO claimed
CN-102659726-A Method for synthesis of dronedarone FUJIAN GUANGSHENGTANG PHARMACEUTICAL CO LTD 2012-09-12 — — CN claimed
EP-2428511-A1 Synthesis of dronedarone and salts thereof USV Limited (IN) 2012-03-14 — — EP claimed
WO-2011158050-A1 PROCESS FOR THE PREPARATION OF DRONEDARONE SANOFI (FR) 2011-12-22 — — WO claimed
CN-102070578-A Preparation method of 2-n-butyl-3-(4-(3-di-n-butylaminopropyl) benzoyl)-5-oxoethyl amino benzofuran SHANGHAI INST PHARM INDUSTRY 2011-05-25 — — CN claimed
CN-100371314-C Benzoyl derivative and hydrochloride thereof and preparation method thereof SANOFI SYNTHELABO (FR) 2008-02-27 — — CN claimed
CN-1769262-A Benzoyl derivative and hydrochloride thereof and preparation method thereof SANOFI SYNTHELABO (FR) 2006-05-10 — — CN claimed
US-6846936-B2 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof SANOFI-SYNTHELABO (FR) 2005-01-25 — — US claimed
CN-1479706-A 2-butyl-3- (4- [ 3- (dibutylamino) propoxy ] benzoyl) -5-nitrobenzofuran hydrochloride and preparation thereof ʥŵ��-�ϳ�ʵ���ҹ�˾ 2004-03-03 — — CN claimed
US-20040010032-A1 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof SANOFI (FR) 2004-01-15 — — US claimed
EP-1351907-A1 2-BUTYL-3-(4- 3(DIBUTYLAMINO)PROPOXY BENZOYL)-5-NITRO-BENZOFURAN HYDROCHLORIDE AND PREPARATION THEREOF Sanofi-Aventis (FR) 2003-10-15 — — EP claimed
WO-2002048078-A1 2-BUTYL-3-(4-[3(DIBUTYLAMINO)PROPOXY]BENZOYL)-5-NITRO-BENZOFURAN HYDROCHLORIDE AND PREPARATION THEREOF SANOFI-SYNTHELABO (FR) 2002-06-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109868-A1 Process for the Preparation of Dronedarone CYP2D6, CYP2B6, CYP2F1 TSHR 4058/4885TDP1 2601/4885ALDH1A1 1489/4885
US-20040010032-A1 2-butyl-3-(4-[3(dibutylamino)propoxy]benzoyl)-5-nitro-benzofuran hydrochloride and preparation thereof CYP2D6, DBF4, DUT TSHR 4002/4885TDP1 1802/4885ALDH1A1 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.